Q-omics provides the consensus-scored TRIM23 profile across patient tissues and cancer cell-line models. TRIM23 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM23 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TRIM23 RNA expression shows 21,533 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TRIM23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM23 survival associations across molecular data types. TRIM23 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM23 RNA expression–survival associations across cancer types. High TRIM23 expression shows unfavorable associations in OV, UVM and STAD, but favorable associations in KIRC, LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM23 RNA expression.
This table summarizes TRIM23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM23 shows lower tumor expression in LUSC, UCEC and THCA and higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher TRIM23 RNA expression in tumor versus normal tissue (log2 FC = +0.482, t-test p < 0.001).
This table shows molecular features associated with TRIM23 in patient tissues and cancer cell lines. In patient samples, TRIM23 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
